The Nerivio Migra is a wireless device that attaches to a patient’s upper arm and administers remote electrical neuromodulation, controlled by the patient’s smartphone. A recent study found that when 252 patients used the wearable device to treat migraine attacks, more than 66 percent experienced pain relief within two hours.
As Theranica now prepares to commercialize the Nerivio Migra in the U.S., CEO Alon Ironi said the company will also be continuing to explore the use of the device’s non-invasive, drug-free technology to treat “at least 7 different painful conditions.”
More articles about health IT:
Harvard Business Review: What boards need to know about AI
ZeOmega AI uses social determinants of health to predict risk of opioid abuse
Wearable neurotech companies need to rein in claims, ethics experts say
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.